Declines Seen in Medical, Nonmedical Use of Prescription Meds Among Teens
By Elana Gotkine HealthDay Reporter
THURSDAY, July 25, 2024 -- U.S adolescents reported declines in medical use and nonmedical use (NMU) of prescription stimulants, opioids, and benzodiazepines from 2009 to 2022, according to a research letter published online July 24 in the Journal of the American Medical Association.
Sean Esteban McCabe, Ph.D., from the University of Michigan School of Nursing in Ann Arbor, and colleagues examined trends in medical use, NMU, diversion sources, and perceived procurement difficulty of prescription medications for NMU among U.S. adolescents using data from the Monitoring the Future self-administered survey for 2009 to 2022. Data were included for 29,220 adolescents (51.84 percent female).
The researchers found that reported lifetime medical use decreased significantly between 2009 and 2022 (23.66 to 16.00 percent) as did past-year NMU (11.49 to 2.38 percent). Significant declines were seen in trends in two diversion sources from 2009-2010 to 2021-2022: from 57.96 to 26.87 percent for those reporting being given prescription medications from a friend and from 44.35 to 19.42 percent for those reported buying medications from a friend. The most prevalent diversion source in 2021 to 2022 was one's own prescription among adolescents reporting NMU (37.37 percent). There was a decrease in the prevalence of adolescents reporting multiple diversion sources (from 56.27 to 29.33 percent). An increase was seen in the prevalence of adolescents who reported that it would probably be impossible for them to obtain prescription medications for NMU, from 35.56 to 48.96 percent.
"Efforts to further reduce NMU and diversion are needed, particularly given the role of counterfeit pills in the adolescent overdose crisis," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2024
Read this next
GLP1RAs Tied to Greater Risk of Diabetic Retinopathy Progression Than SGLT2is
FRIDAY, July 26, 2024 -- In patients with diabetes and established diabetic retinopathy (DR), treatment with glucagon-like peptide 1 receptor agonists (GLP1RAs) is associated with...
Racial Disparities Identified for Time to Diagnosis of Huntington Disease
FRIDAY, July 26, 2024 -- Black individuals are diagnosed with Huntington disease (HD) at least one year later than White individuals, according to a study published online June 21...
Widespread Brain Structural Alterations Seen in Conduct Disorders
FRIDAY, July 26, 2024 -- There are widespread brain structural alterations apparent in conduct disorders, mostly in surface area, according to a study published in the August...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.